GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
- P. McClean, N. Irwin, R. Cassidy, J. Holst, V. Gault, P. Flatt
- Biology, MedicineAmerican Journal of Physiology. Endocrinology and…
- 1 December 2007
Data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet.
GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.
- V. Gault, C. Hölscher
- BiologyEuropean Journal of Pharmacology
- 10 June 2008
Protease-resistant glucose-dependent insulinotropic polypeptide agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid.
- V. Gault, C. Hölscher
- Biology, ChemistryJournal of Neurophysiology
- 1 April 2008
The results demonstrate for the first time that GIP (particularly enzyme-resistant forms) not only directly modulates neurotransmitter release and LTP formation, but also protects synapses from the detrimental effects of beta-amyloid fragments on LTP Formation.
Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
- P. McClean, V. Gault, P. Harriott, C. Hölscher
- BiologyEuropean Journal of Pharmacology
- 25 March 2010
Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo.
- V. Gault, J. Parker, P. Harriott, P. Flatt, F. O'Harte
- Biology, MedicineJournal of Endocrinology
- 1 November 2002
Data indicate that the N-terminally truncated GIP(3-42) fragment acts as a GIP receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
- V. Gault, B. D. Kerr, P. Harriott, P. Flatt
- Biology, MedicineClinical science
- 1 August 2011
It is demonstrated that a combined preparation of the acylated GLP-1 and GIP peptides Liraglutide and N-AcGIP(Lys(37)Myr) markedly improved glucose-lowering and insulinotropic properties in diabetic obesity compared with either incretin mimetic given individually.
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
- Simon Gengler, P. McClean, R. McCurtin, V. Gault, C. Hölscher
- BiologyNeurobiology of Aging
- 1 February 2012
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
- B. Green, V. Gault, F. O’Harte, P. Flatt
- Biology, MedicineCurrent pharmaceutical design
- 31 October 2004
The antidiabetic properties of the best GLP-1 and GIP analogues indeed promise to provide the basis for novel, effective and long-acting drugs for type 2 diabetes therapy and are currently being pursued actively by the pharmaceutical industry.
Sitagliptin, a dipeptidyl peptidase‐4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline
To examine whether prolonged dipeptidyl peptidase‐4 (DPP‐4) inhibition can reverse learning and memory impairment in high‐fat‐fed mice, DPP‐4 inhibition is inhibition is removed from the experimental procedure.
...
...